Ralph A. Nixon

Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease.

Antibodies to the lysosomal hydrolases, cathepsins B and D and beta-hexosaminidase A, revealed alterations of the endosomal-lysosomal system in neurons of the Alzheimer disease brain, which preceded evident degenerative changes and became marked as atrophy, neurofibrillary pathology, or chromatolysis developed. At the earliest stages of cell atrophy, hydrolase-positive lysosomes accumulated at the basal pole and then massively throughout the perikarya and proximal and proximal dendrites of affected pyramidal neurons in Alzheimer prefrontal cortex and hippocampus, far exceeding the changes of normal aging. Secondary lysosomes as well as tertiary residual bodies (lysosomes/lipofuscin) increased implying stimulated, autophagocytosis and lysosomal system activation. Less affected brain regions, such as the thalamus, displayed similar though less extensive alterations. Certain thalamic neurons exhibited a distinctive lysosome-related abnormality characterized by the presence of cell surface blebs of varying size and number filled with intense hydrolase immunoreactivity. At more advanced stages of degeneration in still intact neurons, hydrolase-positive lipofuscin, particularly in the form of abnormally large aggregates, nearly filled the cytoplasm. Similar lipofuscin aggregates were observed in abundance in the extracellular space following cell lysis and were usually associated with deposits of the beta-amyloid protein. Degenerating neurons and their processes were the major source of these aggregates within senile plaques which contained high concentrations of acid hydrolases. We have shown in previous studies that these lysosomal hydrolases in plaques are enzymatically-active. The persistence of lysosomal structures in the brain parenchyma after neurons have degenerated is a striking and potentially diagnostic feature of Alzheimer disease which has not been observed, to our knowledge, in other degenerative diseases. The lysosomal response in degenerating Alzheimer neurons represents a probable link between an early activation of the lysosomal system in at-risk, normal-appearing neurons and the end-stage contribution of lysosomes to senile plaque formation and emphasizes a slowly progressive disturbance of the lysosomal system throughout the development of Alzheimer disease.

The Regulation of Neurofilament Protein Dynamics by Phosphorylation: Clues to Neurofibrillary Pathobiology

Neurofilament proteins are continuously modified during their lifetime by a succession of protein kinases and phosphatases. Site‐specific phosphorylation or dephosphorylation within different polypeptide domains of each neurofilament subunit is now believed to regulate such behaviors of neurofilaments as subunit polymerization and exchange, axonal transport, interactions with other cytoskeletal proteins and degradation. Local regulation of phosphorylation events could account for variations in the size, morphology and dynamics of the neurofilament network in different regions of the neuron. The apparent greater plasticity of the neurofilament network in regions like the perikaryon, initial segment and nodes along the axon may provide some insight into the vulnerability of these regions in neurofibrillary disease.

Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease.

Calpain proteases influence intracellular signaling pathways and regulate cytoskeleton organization, but the neuronal and pathological roles of individual isoenzymes are unknown. In Alzheimers disease (AD), the activated form of calpain I is significantly increased while the fate of calpain II has been more difficult to address. Here, calpain II antibodies raised to different sequences within a cryptic region around the active site, which becomes exposed during protease activation, were shown immunohistochemically to bind extensively to neurofibrillary tangles (NFT), neuritic plaques, and neuropil threads in brains from individuals with AD. Additional pre-tangle granular structures in neurons were also intensely immunostained, indicating calpain II mobilization at very early stages of NFT formation. Total levels of calpain II remained constant in the prefrontal cortex of AD patients but were increased 8-fold in purified NFT relative to levels of calpain I. These results implicate activated calpain II in neurofibrillary degeneration, provide further evidence for the involvement of the calpain system in AD pathogenesis, and imply that neuronal calcium homeostasis is altered in AD.

Colocalization of lysosomal hydrolase and β-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome

The lysosomal hydrolases, cathepsin D (Cat D) and β-hexosaminidase A (HEX), which are normally intracellular enzymes, colocalize with β-amyloid in a subgroup of diffuse plaques in the cerebellum and striatum of individuals with Alzheimers disease or Downs syndrome. Using specific antisera in combination with single- and double-label immunocytochemical techniques, extracellular hydrolase was detected in 30 to 40% of the diffuse plaques in the cerebellar molecular layer and nearly all of the diffuse plaques in the striatum. In both Alzheimers disease and Downs syndrome, about 5 to 10% of the cerebellar Purkinje cells contained abnormally increased numbers of hydrolase-positive lysosomes despite their normal appearance by conventional histologic stains. Occasional atrophic Purkinje cells identified by Nissl stain were intensely immunostained. By confocal imaging analysis, abnormal hydrolase-laden Purkinje cell dendrites were seen coursing through some hydrolase-positive plaques and were continuous with dendritic branches that terminated within deposits of extracellular hydrolase and β-amyloid. In the striatum, intensely immunostained abnormal-appearing neurons were commonly associated with extracellular deposits of hydrolase immunoreactivity and β-amyloid within diffuse plaques and in the less commonly seen classical plaques. In both brain regions, other hydrolase-negative β-amyloid deposits were seen, these being associated with blood vessels. The presence of HEX immunoreactivity in neurons, but not in glia, and its abundance in plaques support earlier studies, suggesting that neurons are the principal source of plaque hydrolase. An endosomal-lysosomal system upregulation, with increased hydrolase expression and extracellular enzyme deposition in plaques, is, like β-amyloid deposition, an early marker of metabolic dysfunction potentially related to primary etiologic events in Alzheimers disease and Downs syndrome.

Slow axonal transport

New studies provide further evidence that the neuronal cytoskeleton is the product of a dynamic interplay between axonal transport processes and locally regulated assembly mechanisms. These data confirm that the axonal cytoskeleton in mammalian systems is largely stationary and is maintained by a smaller pool of moving subunits or polymers. Slow axonal transport in certain lower species, however, may exhibit quite different features.

Proteases of human brain

Growing appreciation of the multiple functions of proteolytic enzymes in intracellular protein degradation and post-translational modification, in the release of biologically active macromolecules and peptides from precursors and in cellular protein regulation and quality control has stimulated interest in proteases in neurobiology and neuropathology. In this article, the proteinases and peptidases thus far studied in the human central nervous system are reviewed with respect to their enzymology, anatomical and cytological distributions and contributions to neurological and psychiatric disease states. Though information concerning brain proteases in man is fragmentary, it suffices to establish the importance of these complex systems for advancing knowledge of human cerebral function in health and disease.

[32P]orthophosphate and [35S]methionine label separate pools of neurofilaments with markedly different axonal transport kinetics in mouse retinal ganglion cells in vivo.

Newly synthesized neurofilament proteins become highly phosphorylated within axons. Within 2 days after intravitreously injecting normal adult mice with [32P]orthophosphate, we observed that neurofilaments along the entire length of optic axons were radiolabeled by a soluble32P-carrier that was axonally transported faster than neurofilaments.32P-incorporation into neurofilament proteins synthesized at the time of injection was comparatively low and minimally influenced the labeling pattern along axons.32P-incorporation into axonal neurofilaments was considerably higher in the middle region of the optic axons. This characteristic non-uniform distribution of radiolabel remained nearly unchanged for at least 22 days. During this interval, less than 10% of the total32P-labeled neurofilaments redistributed from the optic nerve to the optic tract. By contrast, newly synthesized neurofilaments were selectively pulse-labeled in ganglion cell bodies by intravitreous injection of [35S]methionine and about 60% of this pool translocated by slow axoplasmic transport to the optic tract during the same time interval. These findings indicate that the steady-state or resident pool of neurofilaments in axons is not identical to the newly synthesized neurofilament pool, the major portion of which moves at the slowest rate of axoplasmic transport. Taken together with earlier studies, these results support the idea that, depending in part on their phosphorylation state, transported neurofilaments can interact for short or very long periods with a stationary but dynamic neurofilament lattice in axons.

Specificity of calcium-activated neutral proteinase (CANP) inhibitors for human μCANP and mCANP

We investigated the relative inhibition of purified human μCANP and mCANP by five cysteine proteinase inhibitors including N-acetyl-Leu-Leu-nor-leucinal (C-I) and N-acetyl-Leu-Leu-methioninal (C-II), calpeptin, E64, and leupeptin. Based on IC50 measurements, calpeptin and C-I were stronger inhibitors by one to two orders of magnitude than C-II, leupeptin or E64. None of the five inhibitors, however, exhibited greater specificity for human μCANP or mCANP. These results indicate that, although the inhibition of a given cellular event by these compounds may suggest CANP involvement, effects on μCANP cannot be discriminated from those on mCANP.